1. Home
  2. WEC vs NTRA Comparison

WEC vs NTRA Comparison

Compare WEC & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WEC Energy Group Inc.

WEC

WEC Energy Group Inc.

HOLD

Current Price

$117.34

Market Cap

35.3B

Sector

Utilities

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$188.87

Market Cap

32.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEC
NTRA
Founded
1981
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.3B
32.9B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
WEC
NTRA
Price
$117.34
$188.87
Analyst Decision
Buy
Strong Buy
Analyst Count
12
14
Target Price
$119.17
$259.07
AVG Volume (30 Days)
2.0M
1.0M
Earning Date
05-04-2026
05-19-2026
Dividend Yield
3.31%
N/A
EPS Growth
N/A
0.65
EPS
4.81
N/A
Revenue
$9,800,100,000.00
$210,939,000.00
Revenue This Year
$5.14
$16.65
Revenue Next Year
$6.61
$19.22
P/E Ratio
$23.93
N/A
Revenue Growth
13.96
N/A
52 Week Low
$100.64
$125.38
52 Week High
$118.19
$256.36

Technical Indicators

Market Signals
Indicator
WEC
NTRA
Relative Strength Index (RSI) 61.98 33.62
Support Level $103.54 $182.20
Resistance Level N/A $251.09
Average True Range (ATR) 1.78 8.09
MACD -0.27 -1.01
Stochastic Oscillator 89.57 7.21

Price Performance

Historical Comparison
WEC
NTRA

About WEC WEC Energy Group Inc.

WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 32% gas distribution, 10% electric transmission, 7% unregulated renewable energy, and 2% LNG distribution and generation.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: